Drugs / Menitorix
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 35 trials | ||||||
| Phase 3 | NCT00586612 | Dec 2007 → Dec 2008 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00463437 | Apr 2007 → Jan 2008 | diphtheria, hepatitis B virus infection, pneumococcal infection, poliomyelitis +1 | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00384059 | Oct 2006 → Oct 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00326118 | Jun 2006 → Nov 2007 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00322335 | May → Jul 2006 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00503165 | Jul → Aug 2007 | — | Public Health England | Completed | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 2 | NCT00871338 Background | Jun 2009 → Mar 2010 | haemophilus infectious disease, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT02002156 Background | Jun 2014 → Aug 2016 | tuberculosis | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT02526394 Comparator | Sep 2013 → Mar 2017 | meningococcal meningitis, pertussis | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT01896596 Comparator | Jul 2013 → Apr 2017 | haemophilus infectious disease, hepatitis B virus infection, meningococcal infection, pneumococcal infection | Public Health England | Completed | No outcome recorded |
| Phase 4 | NCT00454987 Comparator | May → Oct 2007 | haemophilus meningitis, meningococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Menitorix | “This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050.” NCT00322335 ↗11“Subjects received a single dose of Menitorix™ vaccine co-administered with Priorix™ vaccine.” NCT00326118 ↗ “Hib & Meningococcal C Vaccine (Menitorix™) 811936 Given at 12-15 Months of Age” NCT00454987 ↗ “Repevax + Menitorix” NCT02526394 ↗ |
| Known as | Menitorix, GlaxoSmithKline UK | “Menitorix®, GlaxoSmithKline UK” NCT02002156 ↗ |
| Modality | Vaccine | “Haemophilus influenzae type b and meningococcal C (Hib-MenC) conjugate vaccine” NCT00326118 ↗ |
| Route | Intramuscular | “This was followed by a booster dose of Menitorix™ administered intramuscularly in the left thigh between 13 and 14 months of age in study NCT00323050.” NCT00322335 ↗ |